Trial | NCT00564148  Report issue

Title

Intravitreal Avastin in Proliferative Retinopathies
Intravitreal Injections With Avastin in Proliferative Retinopathies Related to the Production of VEGF Having Different Causes

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    100
The study intends to assess the effect of Avastin injections in different proliferative retinopathies due to different causes
Proliferative retinopathies due to different causes represent important causes for the visual acuity loss. Conventional treatments may sometimes improve the visual function, whereas other times, the visual acuity continue to decrease, in spite of all the medical, surgical or laser treatments.

Intravitreal injections with anti-VEGF agents (ex. Avastin for our trial) seem to be an important tool for certain difficult situations in which at the ocular fundus, out of different reasons (advanced age, diabetes mellitus, retinal veins occlusions, etc)new pathologic vessels appear, causing devastating changes in the posterior and anterior segment as well.
Study Started
Jul 31
2007
Primary Completion
Nov 30
2009
Study Completion
Dec 31
2009
Last Update
Jul 22
2011
Estimate

Drug Avastin

2,5 mg Avastin intravitreal injections every 4 weeks, 6 months consecutively

  • Other names: Bevacizumab

A,1, II Experimental

Criteria 

Inclusion Criteria:

clinical diagnosis of a proliferative retinopathy (AGE RELATED MACULAR DEGENERATION,DIABETIC PROLIFERATIVE RETINOPATHY, etc)
distance acuity < 0.5
age > 20 years

Exclusion Criteria:

noncooperative patients
ocular infections / inflammations
No Results Posted